Vaccine News and Research

Latest Vaccine News and Research

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG.

4 Aug 2020

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

4 Aug 2020

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

Yale researchers develop new mouse model to study SARS-CoV-2 infection

Researchers at Yale University School of Medicine have developed a new mouse model to study SARS-CoV-2 infection and disease and to accelerate testing of novel treatments and vaccines against the novel coronavirus.

4 Aug 2020

Illustrating the dystopic nature of people’s approach to COVID-19

Are we "Waiting for Godot"- A Metaphor for Covid-19 "Waiting for Godot", one of the greatest works of the Theater of the Absurd is used to illustrate the dystopic nature of our approach to COVID-19.

4 Aug 2020

Study identifies possible therapeutic treatment for COVID-19

Yunjeong Kim and Kyeong-Ok "KC" Chang, virologists in the College of Veterinary Medicine at Kansas State University, have published a study showing a possible therapeutic treatment for COVID-19.

3 Aug 2020

Extensive study of SARS-CoV-2 sequencing reveals six strains of the virus

The virus causing the COVID-19 pandemic, SARS-CoV-2, presents at least six strains. Despite its mutations, the virus shows little variability, and this is good news for the researchers working on a viable vaccine.

3 Aug 2020

Oxford University and ZOE join forces to widen access to COVID-19 treatment trials

Oxford University and the COVID Symptom Study app are joining forces to widen access to two clinical trials of potential treatments for COVID-19.

3 Aug 2020

Maternal vaccination could protect infants against RSV illness

Immunizing pregnant women with a potential vaccine against RSV could prevent the most common cause of pneumonia in their babies.

3 Aug 2020

What seniors can expect as their new normal in a post-vaccine world

Imagine this scenario, perhaps a year or two in the future: An effective COVID-19 vaccine is routinely available and the world is moving forward. Life, however, will likely never be the same — particularly for people over 60.

3 Aug 2020

Meningitis case at Children's National Hospital raises concerns about antibiotic resistance

A recent meningitis case at Children's National Hospital raises serious concerns about antibiotic resistance in the common bacterium that caused it, researchers from the hospital write in a case report.

3 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

The race to a coronavirus vaccine

As the number of coronavirus disease (COVID-19) cases skyrocket to a staggering 18 million, the race to attain vaccine approval is on. More than a hundred candidate vaccines are being developed and tested to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, many vaccine candidates are undergoing human stage 2 and 3 trials to prove their efficacy and safety.

2 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

Meta-analysis shows 57% mortality reduction with convalescent plasma in COVID-19

Now, a new study published on the preprint server medRxiv in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in hospitalized COVID-19 patients by an astonishing 57%. This adds evidence for the use of convalescent plasma in the treatment of high-risk patients.

1 Aug 2020

Children carry 100 times more SARS-CoV-2 virus as adults, study says

As the coronavirus disease (COVID-19) continues to wreak havoc across the globe, it has been thought that children mostly seemed to be spared by severe illness. In the majority of cases, children infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only develop a mild illness, with some tagged as asymptomatic.

31 Jul 2020

Brain Navi develops new nasal swab robot to prevent cross infections

Inspired by the pandemic, Brain Navi developed a new robot to perform nasal swab tests autonomously to prevent cross infections so we can save the medical system and reestablish economies.

31 Jul 2020

COVID-19 rapid antibody test receives CE mark and mass production begins

The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium, has received its CE mark. This means it is approved for professional use in the UK and EU.

31 Jul 2020

Touchlight, Cancer Research UK and University of Southampton team up to develop DNA cancer vaccine

Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma.

31 Jul 2020

Researcher uses in silico analysis of SARS-CoV-2 spike protein to fast-track passive immunity

With millions of COVID-19 cases reported across the globe, people are turning to antibody tests to find out whether they have been exposed to the coronavirus that causes the disease. But what are antibodies? Why are they important? If we have them, are we immune to COVID-19? And if not, why not?

30 Jul 2020